Education
About Us
Working with TipRanks
Follow Us
89bio (ETNB)
NASDAQ:ETNB
ETNB Analyst Ratings
Moderate Buy
5 Buy
4 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
ETNB Stock 12 Month Forecast
Average Price Target
$26.64
▲(79.39% Upside)
| Highest Price Target$38.00 | Average Price Target$26.64 | Lowest Price Target$14.50 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
H.C. Wainwright
$32→$14.5
Hold
-2.36%
Downside
Downgraded
09/19/25
Raymond James
―
Hold
―
Downgraded
09/19/25
Wolfe Research
―
Hold
―
Downgraded
09/18/25
RBC Capital
$11→$15
Hold
1.01%
Upside
Reiterated
09/18/25
UBS
$38
Buy
155.89%
Upside
Reiterated
09/18/25
Bank of America Securities
$30→$29
Buy
95.29%
Upside
Reiterated
08/25/25
Evercore ISI
$33→$28
Buy
88.55%
Upside
Initiated
08/22/25
Citi
$25
Buy
68.35%
Upside
Reiterated
08/08/25
Leerink Partners
$37
Buy
149.16%
Upside
Reiterated
08/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: 89bio (NASDAQ: ETNB), Relay Therapeutics (NASDAQ: RLAY) and Ironwood Pharma (NASDAQ: IRWD)We believe NVO's discontinuation of zalfermin supports our view that not all FGF21 analogs are created equal, and reinforces the positive differenation for competing FGF21 analogs, including ETNB's pegoza and AKRO's (Not Rated) efruxifermin, which have both shown compelling and statistically significant fibrosis benefit in multiple Phase 2 trials. Regarding SHTG, ETNB plans to report topline results from ENTRUST in 1Q26, where the primary endpoint will assess the % change from baseline in fasting triglycerides (TG) at week 26. ETNB continues to expect a second pivotal trial in SHTG will be required for approval.
Cantor Fitzgerald
$55
Buy
270.37%
Upside
Reiterated
04/29/25
Goldman Sachs
$11
Hold
-25.93%
Downside
Initiated
03/14/25
Westpark Capital
$29→$21
Buy
41.41%
Upside
Reiterated
02/28/25
Analysts Are Bullish on Top Healthcare Stocks: 89bio (ETNB), Lemaitre Vascular (LMAT)Our thesis on SHTG remains unchanged despite the delay. Yesterday, 89bio announced that the Phase 3 ENTRUST study of pegozafermin for severe hypertriglyceridemia (SHTG) is now scheduled to be unblinded at Week 52, vs. the previous plan at Week 26.
Oppenheimer
―
Hold
―
Reiterated
11/11/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
H.C. Wainwright
$32→$14.5
Hold
-2.36%
Downside
Downgraded
09/19/25
Raymond James
―
Hold
―
Downgraded
09/19/25
Wolfe Research
―
Hold
―
Downgraded
09/18/25
RBC Capital
$11→$15
Hold
1.01%
Upside
Reiterated
09/18/25
UBS
$38
Buy
155.89%
Upside
Reiterated
09/18/25
Bank of America Securities
$30→$29
Buy
95.29%
Upside
Reiterated
08/25/25
Evercore ISI
$33→$28
Buy
88.55%
Upside
Initiated
08/22/25
Citi
$25
Buy
68.35%
Upside
Reiterated
08/08/25
Leerink Partners
$37
Buy
149.16%
Upside
Reiterated
08/07/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: 89bio (NASDAQ: ETNB), Relay Therapeutics (NASDAQ: RLAY) and Ironwood Pharma (NASDAQ: IRWD)We believe NVO's discontinuation of zalfermin supports our view that not all FGF21 analogs are created equal, and reinforces the positive differenation for competing FGF21 analogs, including ETNB's pegoza and AKRO's (Not Rated) efruxifermin, which have both shown compelling and statistically significant fibrosis benefit in multiple Phase 2 trials. Regarding SHTG, ETNB plans to report topline results from ENTRUST in 1Q26, where the primary endpoint will assess the % change from baseline in fasting triglycerides (TG) at week 26. ETNB continues to expect a second pivotal trial in SHTG will be required for approval.
Cantor Fitzgerald
$55
Buy
270.37%
Upside
Reiterated
04/29/25
Goldman Sachs
$11
Hold
-25.93%
Downside
Initiated
03/14/25
Westpark Capital
$29→$21
Buy
41.41%
Upside
Reiterated
02/28/25
Analysts Are Bullish on Top Healthcare Stocks: 89bio (ETNB), Lemaitre Vascular (LMAT)Our thesis on SHTG remains unchanged despite the delay. Yesterday, 89bio announced that the Phase 3 ENTRUST study of pegozafermin for severe hypertriglyceridemia (SHTG) is now scheduled to be unblinded at Week 52, vs. the previous plan at Week 26.
Oppenheimer
―
Hold
―
Reiterated
11/11/24
Best Analysts Covering 89bio
1 Month
xxx
Success Rate
9/12 ratings generated profit
Average Return
+7.85%
reiterated a xxx
rating 5 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +7.85% per trade.
3 Months
xxx
Success Rate
16/23 ratings generated profit
Average Return
+28.18%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +28.18% per trade.
1 Year
Success Rate
14/23 ratings generated profit
Average Return
+80.93%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 60.87% of your transactions generating a profit, with an average return of +80.93% per trade.
2 Years
xxx
Success Rate
17/23 ratings generated profit
Average Return
+59.90%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 73.91% of your transactions generating a profit, with an average return of +59.90% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
ETNB Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Aug 25
Sep 25
Strong Buy
13
9
7
10
12
Buy
2
1
1
0
0
Hold
9
7
8
4
7
Sell
1
2
2
1
0
Strong Sell
0
0
0
0
0
total
25
19
18
15
19
Each month's total comprises the sum of three months' worth of ratings.
ETNB Financial Forecast
ETNB Stock Forecast FAQ
What is ETNB’s average 12-month price target, according to analysts?
Based on analyst ratings, 89bio’s 12-month average price target is 26.64.
What is ETNB’s upside potential, based on the analysts’ average price target?
89bio has 79.39% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is ETNB a Buy, Sell or Hold?
89bio has a consensus rating of Moderate Buy which is based on 5 buy ratings, 4 hold ratings and 0 sell ratings.
What is 89bio’s price target?
The average price target for 89bio is 26.64. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $38.00 ,the lowest forecast is $14.50. The average price target represents 79.39% Increase from the current price of $14.85.
The highest analyst price target is $38.00 ,the lowest forecast is $14.50. The average price target represents 79.39% Increase from the current price of $14.85.
What do analysts say about 89bio?
89bio’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.
How can I buy shares of ETNB?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.